Apimeds Pharmaceuticals US, Inc. Material Event: Understanding the Boardroom Dispute

If you follow Apimeds Pharmaceuticals (APUS), you may have seen confusing headlines about a boardroom dispute. Here is the plain-English breakdown of the company’s March 20, 2026, filing and what it means for your investment.

1. What happened?

On March 20, a group of shareholders led by Inscobee Inc. (which owns about 14.2% of Apimeds stock) attempted to take control of the company. They claimed to have removed all five board members and replaced the CEO, Dr. Elena Vance, and the CFO, Marcus Thorne, with their own team.

The twist: Apimeds states this move is legally invalid. In December 2025, Inscobee signed an agreement giving the Apimeds board the power to vote their shares until the MindWave acquisition is fully integrated. Because this agreement is still active, the company maintains that the group had no legal right to remove the board.

2. Why did it happen?

This conflict stems from the $85 million merger with MindWave Innovations last December. As part of that deal, Inscobee agreed to support the board’s long-term strategy. Apimeds claims Inscobee is now trying to break that deal, likely to sell off MindWave’s assets for a quick profit—a move the current board argues would undermine the company’s research goals.

3. Why does this matter?

This power struggle creates a "governance vacuum," which is a major red flag for any company. Apimeds is currently running a critical Phase II clinical trial for its lead drug, APU-101, which costs $12 million every quarter. If the leadership dispute isn't resolved quickly, it could freeze bank accounts, delay payments to research partners, and potentially trigger debt clauses that might force the company to pay back $22 million in loans immediately.

4. Who is affected?

• Investors: Expect high volatility. The stock price may swing as the market reacts to conflicting news.
• The Company: Apimeds has asked the Delaware Court of Chancery to declare the takeover attempt invalid and is seeking a court order to stop the dissident group from accessing company records.
• Partners: Apimeds has notified its banks and the FDA that only the current board has the authority to sign documents or authorize payments.

5. What happens next?

The company is taking several legal steps to regain control:

• In the U.S.: The Delaware Court of Chancery will likely hold a hearing within two weeks to decide if the voting agreement is valid.
• In Korea: Apimeds has hired legal counsel to sue Inscobee’s leadership for breach of contract and violation of business laws.
• At the Exchange: The company is working with the NYSE to ensure trading remains orderly and to prevent the unauthorized issuance of new shares.

6. What should you know before you act?

• Stay cautious: Legal battles are expensive and can burn through $2 million to $5 million in cash every quarter. This is money that would otherwise go toward drug development.
• Ignore the noise: The company has instructed its transfer agent to reject any voting or share transfer requests from the dissident group.
• Watch the court: The Delaware Court of Chancery will decide the outcome. Until a judge rules, the current board remains in control.

Bottom Line: This is a high-stakes legal standoff. Until the Delaware court provides clarity, the company’s operational stability is at risk. If you are an investor, the most important thing to watch is the upcoming court hearing—that is where the future of the company’s leadership will be decided.

Disclaimer: I’m just breaking down the news for you—this isn't financial advice. Always do your own research before making any trades!